Brain endothelial cell‐targeted gene therapy of neurovascular disorders

Abstract Neurovascular disorders are difficult to treat due to the blood–brain barrier (BBB), which prevents delivery of most drugs from the blood into the brain. Gene therapy can potentially overcome this barrier, but classical vectors are neither efficient nor specific enough to provide long‐lasti...

Full description

Saved in:
Bibliographic Details
Main Authors: Serena Marchiò, Richard L Sidman, Wadih Arap, Renata Pasqualini
Format: Article
Language:English
Published: Springer Nature 2016-05-01
Series:EMBO Molecular Medicine
Online Access:https://doi.org/10.15252/emmm.201606407
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849761556736245760
author Serena Marchiò
Richard L Sidman
Wadih Arap
Renata Pasqualini
author_facet Serena Marchiò
Richard L Sidman
Wadih Arap
Renata Pasqualini
author_sort Serena Marchiò
collection DOAJ
description Abstract Neurovascular disorders are difficult to treat due to the blood–brain barrier (BBB), which prevents delivery of most drugs from the blood into the brain. Gene therapy can potentially overcome this barrier, but classical vectors are neither efficient nor specific enough to provide long‐lasting treatment or avoid off‐target effects. In this issue of EMBO Molecular Medicine, Körbelin et al (2016) describe an engineered adeno‐associated virus (AAV) with exceptional tropism for the brain that restores a normal phenotype in a mouse model of incontinentia pigmenti (IP), a severe human genetic disorder of brain vasculature.
format Article
id doaj-art-ad9b36cec15a47879f662fbb001e7f4a
institution DOAJ
issn 1757-4676
1757-4684
language English
publishDate 2016-05-01
publisher Springer Nature
record_format Article
series EMBO Molecular Medicine
spelling doaj-art-ad9b36cec15a47879f662fbb001e7f4a2025-08-20T03:06:00ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842016-05-018659259410.15252/emmm.201606407Brain endothelial cell‐targeted gene therapy of neurovascular disordersSerena Marchiò0Richard L Sidman1Wadih Arap2Renata Pasqualini3University of New Mexico Comprehensive Cancer CenterDepartment of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical SchoolDivision of Hematology and Oncology, Department of Internal Medicine, University of New Mexico School of MedicineUniversity of New Mexico Comprehensive Cancer CenterAbstract Neurovascular disorders are difficult to treat due to the blood–brain barrier (BBB), which prevents delivery of most drugs from the blood into the brain. Gene therapy can potentially overcome this barrier, but classical vectors are neither efficient nor specific enough to provide long‐lasting treatment or avoid off‐target effects. In this issue of EMBO Molecular Medicine, Körbelin et al (2016) describe an engineered adeno‐associated virus (AAV) with exceptional tropism for the brain that restores a normal phenotype in a mouse model of incontinentia pigmenti (IP), a severe human genetic disorder of brain vasculature.https://doi.org/10.15252/emmm.201606407
spellingShingle Serena Marchiò
Richard L Sidman
Wadih Arap
Renata Pasqualini
Brain endothelial cell‐targeted gene therapy of neurovascular disorders
EMBO Molecular Medicine
title Brain endothelial cell‐targeted gene therapy of neurovascular disorders
title_full Brain endothelial cell‐targeted gene therapy of neurovascular disorders
title_fullStr Brain endothelial cell‐targeted gene therapy of neurovascular disorders
title_full_unstemmed Brain endothelial cell‐targeted gene therapy of neurovascular disorders
title_short Brain endothelial cell‐targeted gene therapy of neurovascular disorders
title_sort brain endothelial cell targeted gene therapy of neurovascular disorders
url https://doi.org/10.15252/emmm.201606407
work_keys_str_mv AT serenamarchio brainendothelialcelltargetedgenetherapyofneurovasculardisorders
AT richardlsidman brainendothelialcelltargetedgenetherapyofneurovasculardisorders
AT wadiharap brainendothelialcelltargetedgenetherapyofneurovasculardisorders
AT renatapasqualini brainendothelialcelltargetedgenetherapyofneurovasculardisorders